entertainment -WSS

entertainment

author：leisure time 2025-09-27 18:36:44 - browse：77373

Fatty liver foregrounds arteries and veins surrounded by red blood cells — health coverage from STAT — Adobe

As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound, they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease.

A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH).

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

WSS

AstraZeneca chief proposes a novel edit to the drug pricing bill

Alabama IVF ruling threatens families facing fatal genetic disease

Alabama hospital puts IVF treatments on hold

STAT readers on older presidents, polypills, Medicare, and more

Crinetics acromegaly drug succeeds in late

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

entertainment

entertainment

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Covid hospitalizations on the rise, Humana says

Heart attack and stroke risk calculators need revising

He's a Nobel laureate. Critics say he was misleading on Covid

Guidelines to prevent youth baseball injuries need more muscle

He's a Nobel laureate. Critics say he was misleading on Covid

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

At least 13 dead in Texas as scorching temps continue

Alabama IVF ruling threatens families facing fatal genetic disease

focus

Trump surgeon general acknowledges mistakes during Covid

Trump surgeon general acknowledges mistakes during Covid

Alabama frozen embryo ruling has major implications for IVF clinics

Snackable artificial intelligence, expert AI, and the pharma industry

Why palliative psychiatry is worth discussing

Alabama hospital puts IVF treatments on hold

leisure time

entertainment

entertainment

entertainment